Basis for physician recommendations for adjuvant radioiodine therapy in early-stage thyroid carcinoma: Principal findings of the Canadian-American thyroid cancer survey

Endocrine Practice

Volumn 14, Issue 2, 2008, Pages 175-184

  Sawka, Anna M ^a,b   Goldstein, David P ^a   Thabane, Lehana ^c,d   Brierley, James D ^a   Tsang, Richard W ^a   Rotstein, Lorne ^a   Kamalanathan, Shamila ^a   Zhao, Boyu ^a   Gafni, Amiram ^c,e   Straus, Sharon ^f,g   Ezzat, Shereen ^b,h,i,j  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF CALGARY   (Canada)

^h MOUNT SINAI HOSPITAL   (Canada)

ⁱ Freeman Centre for Endocrine Oncology   (Canada)

^j PRINCESS MARGARET HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE;

ARTICLE; CANADA; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; DRUG EFFICACY; EARLY CANCER; FEMALE; FOLLOW UP; HUMAN; LIKERT SCALE; MALE; MEDICAL PRACTICE; PATIENT DECISION MAKING; PHYSICIAN; RATING SCALE; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; UNITED STATES; CLINICAL PRACTICE; DECISION MAKING; EPIDEMIOLOGY; PAPILLARY CARCINOMA; PATHOLOGY; QUESTIONNAIRE; STANDARD; STATISTICS; THYROID TUMOR;

CANADA; CARCINOMA, PAPILLARY; DECISION MAKING; HEALTH CARE SURVEYS; HUMANS; IODINE RADIOISOTOPES; NEOPLASM STAGING; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; THYROID NEOPLASMS; UNITED STATES;

EID: 44049087181     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.14.2.175     Document Type: Article

References (54)

1. Canadian Cancer Society, National Cancer Institute of Canada, Public Health Agency of Canada, Statistics Canada. Canadian cancer statistics 2006. Available at: http://www.cancer.ca/vgn/images/portal/cit-86751114/31/21/ 935505792cw-2006stats-en.pdf.pdf. Accessed for verification December 26, 2007.
2. Ahmedin J, Taylor M, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
3. Hayat MJ, Howlader N, Reichman E, Edwards BK. Cancer statistics, trends, and multiple primary cancers from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007;12:20-37.
4. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164-2167.
5. Park SH, Suh EH, Chi JG. A histopathologic study on 1,095 surgically resected thyroid specimens. Jpn J Clin Oncol. 1988;18:297-302.
6. Cancer Care Ontario/Action Cancer Ontario. Cancer incidence and mortality in Ontario, 1964-2002. Available at: http://www.cancercare.on.ca/ index-statisticsThyroid.htm. Accessed for verification December 26, 2007.
7. Brierley JD, Panzarella T, Tsang RW, Gospodarowicz MK, O'Sullivan B. A comparison of different staging systems predictability of patient outcome: thyroid carcinoma as an example. Cancer. 1997;79:2414-2423.
8. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijn JA, Smit JW. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006;91:313-319.
9. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer. 1998;83:2638-2648.
10. Shaha AR. The National Cancer Data Base report on thyroid carcinoma: reflections of practice patterns. Cancer. 1998;83:2434-2436.
11. Cooper DS, Doherty GM, Haugen BR, et al (The American Thyroid Association Guidelines Task Force). Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109-142.
12. National Cancer Institute, U.S. National Institutes of Health. Thyroid cancer treatment (PDQ). Available at: http://www.cancer.gov/ cancertopics/pdq/treatment/thyroid/healthprofessional/allpages. Accessed for verification December 26, 2007.
13. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W (European Thyroid Cancer Task Force). European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium [published correction appears in Eur J Endocrinol. 2006;155:385]. Eur J Endocrinol. 2006;154:787-803.
14. Thyroid Carcinoma Task Force. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. Endocr Pract. 2001;7:202-220.
15. British Thyroid Association, Royal College of Physicians. Guidelines for the management of thyroid cancer, 2007. Available at: http://www.british-thyroid-association.org/guidelines.htm. Accessed for verification December 26, 2007.
16. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89:3668-3676.
17. Lin WY, Shen YY, Wang SJ. Short-term hazards of low-dose radioiodine ablation therapy in postsurgical thyroid cancer patients. Clin Nucl Med. 1996;21:780-782.
18. Rosario PW, Maia FF, Barroso A, Padrão EL, Rezende L, Purisch S. Sialoadenitis following ablative therapy with high doses of radioiodine for treatment of differentiated thyroid cancer [article in Portuguese]. Arq Bras Endocrinol Metab. 2004;48:310-314.
19. Hyer S, Vini L, O'Connell M, Pratt B, Harmer C. Testicular dose and fertility in men following I(131) therapy for thyroid cancer. Clin Endocrinol (Oxf). 2002;56:755-758.
20. Raymond JP, Izembart M, Marliac V, et al. Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine. J Clin Endocrinol Metab. 1989;69:186-190.
21. Souza Rosário PW, Alvarenga Fagundes T, Villas-Boas Fagundes AS, et al. Ovarian function after radioiodine therapy in patients with thyroid cancer. Exp Clin Endocrinol Diabetes. 2005;113:331-333.
22. Schlumberger M, De Vathaire F, Ceccarelli C, et al. Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med. 1996;37:606-612.
23. Grünwald F, Schomburg A, Menzel C, et al. Changes in the blood picture after radioiodine therapy of thyroid cancer [article in German]. Med Klin (Munich). 1994;89:522-528.
24. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003;89:1638-1644.
25. Günter HH, Schober O, Schwarzrock R, Hundeshagen H. Long-term hematologic changes caused by radioiodine treatment of thyroid cancer. II. Bone marrow changes including leukemia [article in German]. Strahlenther Onkol. 1987;163:475-485.
26. Schober O, Günter HH, Schwarzrock R, Hundeshagen H. Long-term hematologic changes caused by radioiodine treatment of thyroid cancer. I. Peripheral blood changes [article in German]. Strahlenther Onkol. 1987;163:464-474.
27. Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid. 2003;13:265-271.
28. Laupa MS, Toth BB, Keene HJ, Sellin RV. Effect of radioactive iodine therapy on salivary flow rates and oral Streptococcus mutans prevalence in patients with thyroid cancer. Oral Surg Oral Med Oral Pathol. 1993;75:312-317.
29. Caglar M, Tuncel M, Alpar R. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment. Clin Nucl Med. 2002;27:767-771.
30. Burns JA, Morgenstern KE, Cahill KV, Foster JA, Jhiang SM, Kloos RT. Nasolacrimal obstruction secondary to I(131) therapy. Ophthal Plast Reconstr Surg. 2004;20:126-129.
31. Ceccarelli C, Bencivelli Q, Morciano D, Pinchera A, Pacini F. 131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study. J Clin Endocrinol Metab. 2001;86:3512-3515.
32. Streiner DL, Norman GR. Scaling responses. In: Health Measurement Scales: A Practical Guide to Their Development and Use. 2nd ed. Oxford, UK: Oxford University Press, 1995: 34-38.
33. American Thyroid Association. Find a thyroid specialist. 2007. Available at: http://www.thyroid.org/patients/specialists.php3. Accessed for verification December 26, 2007.
34. Kellerman SE, Herold J. Physician response to surveys: a review of the literature. Am J Prev Med. 2001;20:61-67.
35. Field TS, Cadoret CA, Brown ML, et al. Surveying physicians: do components of the "Total Design Approach" to optimizing survey response rates apply to physicians? Med Care. 2002;40:596-605.
36. Cronbach LJ. Essentials of Psychological Testing. 5th ed. New York, NY: Harper Collins Publishing, 1990.
37. Streiner DL. Figuring out factors: the use and misuse of factor analysis. Can J Psychiatry. 1994;39:135-140.
38. Hosmer DW, Hosmer T, Le Cesseie S, Lemeshow S. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med. 1997;16:965-980.
39. Solomon BL, Wartofsky L, Burman KD. Current trends in the management of well differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab. 1996;81:333-339.
40. Hay ID, McConahey WM, Goellner JR. Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc. 2002;113:241-260.
41. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002;26:879-885.
42. Hay ID. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol. 2006;94:692-700.
43. Brierley J, Tsang R, Panzarella T, Bana N. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. Clin Endocrinol (Oxf). 2005;63:418-427.
44. Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16:1229-1242.
45. Hackshaw A, Harmer C, Mallick U, Haq M, Franklyn JA. 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrinol Metab. 2007;92:28-38.
46. Weinfurt KP. Outcomes research related to patient decision making in oncology. Clin Ther. 2003;25:671-683.
47. Levinson W, Kao A, Kuby A, Thisted RA. Not all patients want to participate in decision making: a national study of public preferences. J Gen Intern Med. 2005;20:531-535.
48. Whelan TJ, Loprinzi C. Physician/patient decision aids for adjuvant therapy. J Clin Oncol. 2005;23:1627-1630.
49. Whelan T, Sawka C, Levine M, et al. Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. J Natl Cancer Inst. 2003;95:581-587.
50. Irwin E, Arnold A, Whelan TJ, Reyno LM, Cranton P. Offering a choice between two adjuvant chemotherapy regimens: a pilot study to develop a decision aid for women with breast cancer. Patient Educ Couns. 1999;37:283-291.
51. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001; 19:980-991.
52. Ravdin PM. A computer program to assist in making breast cancer adjuvant therapy decisions. Semin Oncol. 1996;23(1 Suppl 2):43-50.
53. Ravdin PM. A computer based program to assist in adjuvant therapy decisions for individual breast cancer patients. Bull Cancer. 1995;82(Suppl 5):561S-564S.
54. Peele PB, Siminoff LA, Xu Y, Ravdin PM. Decreased use of adjuvant breast cancer therapy in a randomized controlled trial of a decision aid with individualized risk information. Med Decis Making. 2005;25:301-307.